CAN FITE BIOPHARMA LTD-ADR (CANF)
US13471N3008 - ADR
ChartMill assigns a Buy % Consensus number of 83% to CANF. The Buy consensus is the weighted average rating of the current analysts ratings.
CANF was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about CANF.
CANF was analyzed by 7 analysts. More opinions would make the average more meaningful.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-12-05 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-11-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-10 | EF Hutton | Maintains | Buy -> Buy |
| 2024-09-24 | EF Hutton | Maintains | Buy -> Buy |
| 2024-08-30 | EF Hutton | Maintains | Buy -> Buy |
| 2024-07-17 | EF Hutton | Initiate | Buy |
| 2024-05-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-10-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-06-02 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-13 | HC Wainwright & Co. | Reiterate | Buy |